Abstract Number: VPB0133
Meeting: ISTH 2022 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: COVID-19 is associated with an increased risk of venous thrombosis, even when patients are on standard-dose antithrombotic prophylaxis. Hence, the identification of biomarkers of thrombosis helps tailoring dosage of antithrombotic prophylaxis. D-dimer has been extensively employed as a biomarker and cut-off values at hospital admission have been proposed to stratify the risk of thrombosis and make decision on prophylaxis. However, D-dimer measurement is not standardized, and it is unknown if the cut-off values used for decision making can be used interchangeably between methods.
Aims: To assess for concordance of results obtained with different commercially available laboratory methods measuring D-dimer.
Methods: Plasma samples collected from COVID-19 patients at the Hospital of Cremona were evaluated for D-dimer with three widely used immunoturbidimetric methods (Liatest D-di, Stago, Asnieres, France; D-dimer HS 500, Werfen, Orangeburg, NY; Innovance D-dimer, Siemens, Marburg, Germany).
Results: A total of 87 COVID-19 patients [54 male and 33 female, median age of 73 years (range 28-98)] were enrolled in the study. No significant differences were found between mean D-dimer concentrations obtained with the three methods even when stratifying D-dimer levels in 4 groups ( < 1000, 1000-2000, 2000-5000, >5000 ng/mL) (Figure 1). The three methods showed substantial result agreement [Stago-vs-Werfen and Siemens-vs-Stago (Cohen’s kappa coefficient of 0.760 and 0.699, respectively)] to an almost perfect agreement [Siemens-vs-Werfen (Cohen’s kappa coefficient of 0.811)], with a p-value < 0.001. Results from the three methods showed a good linear correlation (Rho=0.94) (Figure 2).
Conclusion(s): The relatively good concordance of D-dimer results among the three investigated methods indicates that D-dimer cut-off values could be used interchangeably regardless of the method used for testing. The results pave the way to clinical trials aimed to assess the value of D-dimer as a biomarker to make decision on the intensity of antithrombotic prophylaxis in COVID-19 patients.
To cite this abstract in AMA style:
Capecchi M, Scalambrino E, Clerici M, Testa S, Dellanoce C, Peyvandi F, Tripodi A. Evaluation of D-dimer Concentrations Measured With Three Methods in Patients With COVID-19 [abstract]. https://abstracts.isth.org/abstract/evaluation-of-d-dimer-concentrations-measured-with-three-methods-in-patients-with-covid-19/. Accessed March 21, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-d-dimer-concentrations-measured-with-three-methods-in-patients-with-covid-19/